Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy

Hamza, Amal H.; Al-Bishri, Widad; Damiati, Laila A.; Ahmed, Hanaa H.

doi:10.1080/0886022x.2016.1244080

Cited by 35 publications

(24 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This indicates that EVs and cytokine release might be more relevant for therapeutic actions than cells themselves ( 197 ). Similarly, the immunomodulatory properties are reported and resulted in the reduction of macrophage infiltration, MCP-1 expression in tissues, and reduction of inflammatory cytokines ( 89 , 251 , 259 , 261 , 262 ). These findings clearly suggest that the metabolic environment has an important impact on the performance of MSC (by deactivation or detrimental shift of their properties).…”

Section: Msc Therapy In the Treatment Of Kidney Diseases: State Of Thmentioning

confidence: 75%

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

et al. 2018

View full text Add to dashboard Cite

Within the last years, the use of stem cells (embryonic, induced pluripotent stem cells, or hematopoietic stem cells), Progenitor cells (e.g., endothelial progenitor cells), and most intensely mesenchymal stromal cells (MSC) has emerged as a promising cell-based therapy for several diseases including nephropathy. For patients with end-stage renal disease (ESRD), dialysis or finally organ transplantation are the only therapeutic modalities available. Since ESRD is associated with a high healthcare expenditure, MSC therapy represents an innovative approach. In a variety of preclinical and clinical studies, MSC have shown to exert renoprotective properties, mediated mainly by paracrine effects, immunomodulation, regulation of inflammation, secretion of several trophic factors, and possibly differentiation to renal precursors. However, studies are highly diverse; thus, knowledge is still limited regarding the exact mode of action, source of MSC in comparison to other stem cell types, administration route and dose, tracking of cells and documentation of therapeutic efficacy by new imaging techniques and tissue visualization. The aim of this review is to provide a summary of published studies of stem cell therapy in acute and chronic kidney injury, diabetic nephropathy, polycystic kidney disease, and kidney transplantation. Preclinical studies with allogeneic or xenogeneic cell therapy were first addressed, followed by a summary of clinical trials carried out with autologous or allogeneic hMSC. Studies were analyzed with respect to source of cell type, mechanism of action etc.

show abstract

Section: Msc Therapy In the Treatment Of Kidney Diseases: State Of Thmentioning

confidence: 75%

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Furthermore, the main kidney nephron-regulatory genes have been described, such as SALL1, PAX2, WT1, Cytokeratin 19 (CK19), CD133, Podocalyxin-like protein 1 ( PODXL ), HOXD11 , HNF1B , BRN1, Lhx1 and Pax8 [ 13 – 18 ]. Adult and fetal bone marrow-derived mesenchymal stem cells (BM-MSCs) have been shown to be capable of repairing renal function deficits [ 19 , 20 ]. BM-MSCs have potent immunosuppressive properties and their potential application in acute kidney injury animal models has been studied recently [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

The presence of human mesenchymal stem cells of renal origin in amniotic fluid increases with gestational time

et al. 2018

View full text Add to dashboard Cite

BackgroundEstablished therapies for managing kidney dysfunction such as kidney dialysis and transplantation are limited due to the shortage of compatible donated organs and high costs. Stem cell-based therapies are currently under investigation as an alternative treatment option. As amniotic fluid is composed of fetal urine harboring mesenchymal stem cells (AF-MSCs), we hypothesized that third-trimester amniotic fluid could be a novel source of renal progenitor and differentiated cells.MethodsHuman third-trimester amniotic fluid cells (AFCs) were isolated and cultured in distinct media. These cells were characterized as renal progenitor cells with respect to cell morphology, cell surface marker expression, transcriptome and differentiation into chondrocytes, osteoblasts and adipocytes. To test for renal function, a comparative albumin endocytosis assay was performed using AF-MSCs and commercially available renal cells derived from kidney biopsies. Comparative transcriptome analyses of first, second and third trimester-derived AF-MSCs were conducted to monitor expression of renal-related genes.ResultsRegardless of the media used, AFCs showed expression of pluripotency-associated markers such as SSEA4, TRA-1-60, TRA-1-81 and C-Kit. They also express the mesenchymal marker Vimentin. Immunophenotyping confirmed that third-trimester AFCs are bona fide MSCs. AF-MSCs expressed the master renal progenitor markers SIX2 and CITED1, in addition to typical renal proteins such as PODXL, LHX1, BRN1 and PAX8. Albumin endocytosis assays demonstrated the functionality of AF-MSCs as renal cells. Additionally, upregulated expression of BMP7 and downregulation of WT1, CD133, SIX2 and C-Kit were observed upon activation of WNT signaling by treatment with the GSK-3 inhibitor CHIR99201. Transcriptome analysis and semiquantitative PCR revealed increasing expression levels of renal-specific genes (e.g., SALL1, HNF4B, SIX2) with gestational time. Moreover, AF-MSCs shared more genes with human kidney cells than with native MSCs and gene ontology terms revealed involvement of biological processes associated with kidney morphogenesis.ConclusionsThird-trimester amniotic fluid contains AF-MSCs of renal origin and this novel source of kidney progenitors may have enormous future potentials for disease modeling, renal repair and drug screening.Electronic supplementary materialThe online version of this article (10.1186/s13287-018-0864-7) contains supplementary material, which is available to authorized users.

show abstract

“…The overexpression of Arg1 reversed the inhibition of the peroxisomal proliferator-activated receptor gamma coactivator 1α (PGC-1α) in tubular epithelial cells (TECs), thereby correcting the mitochondrial dysfunction of TECs. MSCs treatment was reported to be able to effectively inhibit the expression of MCP-1 and macrophages in ltration in the kidney [31], while elevated expressions of MCP-1 and IL-8 were also reported [24].…”

Section: Mononuclear Phagocytesmentioning

confidence: 99%

Mesenchymal Stem Cells Transplantation in Diabetic Kidney Diseases: A Systematic Review and Meta-analysis

Lin¹,

Yang²,

Chen³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Mesenchymal stem cells (MSCs) therapy shows great promise for diabetic kidney diseases (DKD) patients. Researches have been carried out on this topic in recent years. The main thrust of this paper is to evaluate the therapeutic effects of MSCs on DKD by a meta-analysis and systematically review the mechanism therein. Method: An electronic search of PubMed and U.S National Library of Medicine (NLM) was performed for all articles about the MSCs therapy for DKD without species limitation up to January, 2020. Data were pooled for analysis with Stata SE 12. Result: MSCs-treated group showed great significant hypoglycemic effect at 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months and 6 months. Total hypoglycemic effect was analyzed (SMD=-1.954, 95%CI: -2.389 to -1.519, I²= 85.1%, p＜0.001). Total effects on serum creatinine (SCr), blood urea nitrogen (BUN) were analyzed, suggesting MSCs decreased the SCr and BUN and had an effect on amelioration of impaired renal function (SCr: SMD= -4.838, 95%CI: -6.789 to -2.887, I²= 90.8%, p＜0.001; BUN: SMD= -4.912, 95%CI: -6.402 to -3.422, I²= 89.3 %, p＜0.001). Creatinine clearance rate (CCr) was found decreased in the MSCs-treated group at 2 months. MSCs therapy decreased the excretion of urinary albumin. The fibrosis indicators were detected, and the result showed that transforming growth factor-β, Collagen-I, fibronectin and α-smooth muscle actin were seen decreased significantly in the MSCs-treated group. Conclusion: MSCs might improve animal body weight, glycemic control and pancreas islets function to secrete insulin, and reduced the SCr, BUN, CCr, urinary protein and renal hypertrophy. MSCs can reduce the expression of inflammatory mediators and alleviate renal fibrosis. MSCs therapy is a potential treatment for DKD.

show abstract

Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy

Cited by 35 publications

References 46 publications

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

The presence of human mesenchymal stem cells of renal origin in amniotic fluid increases with gestational time

Mesenchymal Stem Cells Transplantation in Diabetic Kidney Diseases: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About